Efficacy of tenofovir in covid-19

Therapeutic Effect of Tenofovir and hydroxychloroquine combination therapy compared to chloroquine alone in patients with COVID-19

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200421047155N1

Enrollment

Registered

2020-04-25

Start date

2020-04-29

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: PO Hydroxychloroquine 200 mg and PO tenofovir 300 mg once a day for 7 days. Intervention 2: Control group: PO Hydroxychloroquine 200 mg once a day for 7 days.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with COVID-19 pulmonary infection Established diagnosis of COVID-19 with RTPCR Patients older than 18 years

Exclusion criteria

Exclusion criteria: Reinfection with COVID-19 Pregnancy Patients with immunodeficiency Individuals who are reluctant to participate in study Prior history of allergy to used drugs Documented history of any other medical condition for which the patient require to use a certain medication routinely. Creatinin clearance less than 30 mg/min Oxygen Saturation (SpO2) less than 40% ICU patients

Design outcomes

Primary

Measure	Time frame
Vital signs. Timepoint: daily. Method of measurement: direct physical examination.;Body temperature. Timepoint: daily. Method of measurement: thermometer.;White blood cell count. Timepoint: daily. Method of measurement: blood sample analysis.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahram Habibzadeh

Ardabil University of Medical Sciences

shahramhabibzadeh@gmail.com+98 45 3325 1401

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026